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I. General Introduction 
A. Chronic Kidney Disease: Overview and Current Concepts 
Chronic kidney disease (CKD) is a generalized term for a variety of chronic 
conditions that result in compromised kidney functions[l]. Under normal 
physiologic conditions, the kidneys serve several functions: regulation of fluid 
volume and the acidlbase balance of plasma; excretion of nitrogenous waste; 
synthesis of erythropoietin, 1,25-dihydroxy-cholecalciferol, and renin; and 
different drug metabolism[2]. Kidney function is assessed by the glomerular 
filtration rate (GFR), which is estimated by the use of the following formula[3]: 
GFR (mumin per 1.73 m2) = 186 x (S~,)- '. '~~X ( ~ ~ e ) - ~ . ~ ~ ~  x (0.742 if female) 
x (1.21 0 if African-American), 
where Sc, is serum creatinine concentration in mgIdL, and age is in years. 
Based on the estimated GFR, there are five stages of CKD[3] as presented in 
Table 1. CKD stage 5, known as End-Stage Renal Disease (ESRD), is defined 
by GFR <15 mllminll .73m2 and characterized by bilateral, progressive, chronic 
deterioration of nephrons, which are the kidney functional units. The kidneys are 
no longer able to maintain normal homeostasis resulting in uremia caused by 
renal failure, retention of excretory products, and interference with endocrine and 
metabolic functions[4]. Stages 3 and 4 can also be characterized by uremia, but 
usually in lower levels than stage 5[5]. Stage 5 is caused by any condition that 
could potentially destroy the nephrons, but the most common causes are 
diabetes mellitus, hypertension, and glomerulonephritis[6]. 
When the patient is diagnosed with CKD stage 5, the goals of treatment are to 
maintain quality of life, control disease progression and prevent further 
complications. At this stage, treatment focuses on dietary modification in an 
effort to decrease the retention of nitrogeneous waste products and control fluid 
and electrolyte imbalances[7]. When conservative treatment fails and the 
number of functional nephrons is reduced to the point that the kidneys can no 
longer filter the blood and adequately remove nitrogen-containing compounds, 
either renal replacement therapy or renal transplantation is necessary[8]. 
Renal replacement therapy (dialysis) is a medical procedure that facilitates the 
removal of water and waste products such as creatinine and urea from the blood. 
More than 350,000 individuals receive dialysis in the United States at a cost of 
more than $7 billion per year[9]. The procedure can be accomplished by ei,ther 
peritoneal dialysis or hemodialysis. Peritoneal dialysis involves infusion of a 
hypertonic solution into the peritoneal cavity 4 to 5 times per day via a 
permanently placed peritoneal catheter[lO]. 
The most common type of renal replacement therapy is hemodialysis therapy 
(HD), with approximately 90% of dialysis patients receiving this form of 
treatment[9]. HD treatments are performed every two or three days, usually 
three or four hours each through vascular access connected to the hemodialysis 
device. Vascular access is accomplished by a permanent and surgically-placed 
arteriovenous (AV) fistula, a graft or a venous catheter. From 1996 to 2007, AV 
fistula use rose from 24% to 47% among HD patients in the US[1 I ] .  Despite 
being a life-saving technique, HD only provides about 15% nephron function[l2] 
and the I-year survival rate is 78%, while the 5-year survival rate is 28%[13]. 
The procedure requires a substantial time commitment from the patient and 
potential complications include potential infection of the fistulalgraft site, 
septicemia, infective endocarditis, cardiovascular disease, hypotension[l4], 
hypoxemia, and arrythmias[l5]. Renal transplantation is a long-term alternative 
to dialysis, but in itself is also associated with a significant number of 
complications such as cardiovascular complications[l6] and increased 
susceptibility to infection or malignancies[l7] despite offering obvious 
advantages such as elimination of dialysis time commitment, fewer diet and fluid 
restrictions, and a better quality of life[l2]. 
CKD is a major global health issue. It is estimated that up to 19 million 
Americans have CKD and 350,000 are currer~tly on dialysis[l8]. Each year, 
approximately 79,000 new cases of stage 5 CKD are diagnosed-a rate of 1.3 in 
10,000 persons. Approximately 60,000 Americans die annually as a result of 
stage 5 with cardiovascular disease being the main cause of mortality in this 
population[l9]. 
6. Inflammation: Role in Chronic Kidney Disease and 
Outcomes 
lnflammation is the biological response of tissue to harmful stimuli such as 
pathogens or irritants[20]. Research has shown inflammation to be a common 
feature in patients suffering from CKD. 30-50% of dialysis patients showed 
evidence of an elevated inflammatory response as indicated by high levels of 
serum C-reactive protein (CRP) [21]. Other studies have found similar results in 
regards to CRP levels in ESRD patients[22-241, 
Identifying the sources of inflammation in CKD patients is still under invedigation 
Evidence supports the idea that deterioration of renal function is associated with 
increased serum cytokine levels[25], while other studies showed that increased 
levels of advanced glycation end products due to decreased renal clearance are 
contributory factors to vascular inflammation [26]. Persistent infections such as 
Chlamydia pneumoniae[27, 281, clotted access grafts[29], and dental 
infections[30, 311 have also been suggested as possible sources of inflammatory 
responses in CKD patients. 
Over the past decade, inflammation has been found to play a strong role in the 
pathogenesis of atherosclerosis in patients with ESRD[32] and associations 
between inflammation and endothelial dysfunction have been documented[21]. 
Inflammatory markers such as high sensitivity C-reactive protein (hsCRP) and 
the pro-inflammatory cytokine interleukin-6 (IL-6) are elevated in ESRD patients 
with cardiovascular disease (CVD)[33]. CRP is a powerful risk predictor for the 
development of CVD[34-361, and this inflammatory burden has been suggested 
to be a significant contributor to the high CVD-induced mortality rate in dialysis 
patients[37]. 
In addition, inflammatory markers including serum CRP and IL-6 have been 
documented as strong predictors of HD poor outcome. Elevated CRP levels 
have been associated with increased mortality in both hemodialysis[35, 38, 391 
and peritoneal dialysis patients[40], as well as otherwise healthy adults[41]. 
Elevated serum IL-6 levels have also been shown to predict myocardial infarction 
in non-renal patients, as well as mortality in the elderly[42, 431. 
C. Periodontitis: Association with Systemic Inflammation 
Periodontal diseases are chronic, predominantly Gram-negative infections of the 
oral cavity that are initiated in ,the gingiva and, if untreated, lead to alveolar bone 
destruction and eventual tooth loss[44, 451. Collectively, periodontal diseases 
affect over 70 percent of the adult population[46]. 
During the past two decades, a field of periodontal research known as 
"periodontal medicine" has emerged[47], investigating the link between 
periodontal disease and other systemic diseases. Recent evidence suggests 
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that there may be an association between periodontal infections and several 
systemic conditions including diabetes[48, 491, pneumonia[50], cardiovascular 
disease[5 1-54], and adverse pregnancy outcomes[55, 561, although other 
investigators have found conflicting results[57, 581. 
For more than a century, clinical researchers have been investigating the biologic 
mechanism that could explain the link between periodontal infections and 
systemic inflammatory diseases. In 1900, Hunter proposed the "Focal lnfection 
Theoryn[59], which supports the role of bacterial by-products from a chronic, 
localized infection that could be disseminated throughout the body and cause 
disease in other organs[60]. This idea led to preventative full-mouth extractions 
in patients assessed susceptible to any diseases. This practice was based on 
anecdotal evidence. Full mouth tooth extraction often failed to prevent systernic 
diseases[61] confirming that the hypothesis was not valid. As a result, the Focal 
lnfection Theory collapsed by the 1950s[62]. Recently, periodontal research has 
focused on systemic conditions such as diabetes mellitus, cardiovascular 
disease, and CKD that have been shown to have an inflammation-linked 
pathogenesis [33, 63, 641. The underlying hypothesis is that periodontitis may 
contribute to overall systemic inflammation and affect the existing systemic 
disease status. Evidence has shown elevated serum levels of CRP as well as 
inflammatory cytokines such as IL-6 in patients with periodontal disease [65-671. 
The idea that periodontal infections can contribute to systemic inflammation is 
further validated by evidence indicating that treatment of periodontal disease can 
reduce systemic levels of CRP, IL-6[68-701, and improve endo,thelial function[63, 
70-721. 
Based on the above, the underlying hypothesis of this research project was 
developed as shown below: CKD subjects compared to healthy controls have 
higher prevalence of periodontal infections that alter systemic inflammatory 
status leading to poor renal outcome. 
II. Periodontitis in CKD Patients 
A. Obiectives 
1. Hypothesis: 
CKD subjects have higher prevalence of severe periodontitis than 
healthy controls. 
2. Specific Objectives: 
Using a population of stable CKD patients and healthy controls, we 
aimed to: 
a> Assess the prevalence of severe periodontitis in HD 
and pre-dialysis patients and compare to healthy 
controls. 
Assess the relationship between periodontal status and 
renal function. 
Introduction: 
Evidence on the prevalence of periodontitis in the CKD population is conflicting. 
In a cross-sectional study of 45 dialysis patients, Naugle and co-workers[73] 
found that 100% of subjects displayed some form of periodontal disease, 
although the majority of patients (64%) had mild periodontitis or gingivitis. 
Conversely, Marakoglu et a1[74] found no difference in clinical parameters of 
periodontal disease between 36 chronic renal failure patients on hemodialysis 
and 36 age and gender matched systemically healthy controls. The authors 
concluded that chronic renal failure did not seem to be a risk factor for more 
severe periodontal destruction. More recent studies have reported more severe 
periodontal destruction in renal failure patients compared to the general 
population[75]. In addition, CKD subjects are characterized by some well- 
established risk factors of periodontitis such as poor oral hygiene[76] and 
diabetes[77]. Because of the conflicting available evidence, it was the goal of 
this study to further explore the prevalence of periodontitis and its role on 
systemic inflammation in CKD patients. 
C. Materials & Methods: 
1. Subject recruitment 
Based on studies by Borawski et a1.1751 and Chen et a1.1761, our power analysis 
estimated that 27 HD, 27 pre-dialysis CKD and 58 systemically healthy control 
patients would need to be recruited in order to identify a difference in 
periodontitis prevalence between HD, CKD and systemically healthy. However, 
since this was a one-year pilot feasibility study, we limited our sample size. 
Twenty-one CKD patients, including twelve hemodialysis (HD) and nine stage 3- 
4 (pre-dialysis) CKD patients were recruited from the University of Connecticut 
Health Center (UCHC) Dialysis Unit and Nephrology Clinic after consultation with 
their nephrologist. In addition, thirteen non-CKD patients were recruited from 
UCHC personnel and served as healthy controls. Smokers were excluded from 
the study. The inclusion criteria were as follows: 1) a minimum of 15 teeth 2) no 
use of antibiotics within the past month 3) no periodontal treatment within the 
past year 4) absence of systemic infection 5) for the HD patients, no history of 
vascular access infection within the past month. The study was approved by the 
UCHC Institutional Review Board (IRB). All patients signed a consent form to 
enter the study. 
2. Data Collection 
Medical Data 
Medical information of the CKD patients was extracted from hospital records 
using a standardized extraction form (see Appendix) that included age, gender, 
ethnicity, weight, height, diabetes status, history of cardiovascular disease and 
hypertension, primary diagnosis, medication history including use of anti- 
hyperlipidemic or non-steroidal anti-inflarr~matory agents. Additionally, the most 
recent biochemical data were extracted from the charts including serum albumin, 
blood urea nitrogen (BUN), creatinine, ferritin level, total iron binding capacity 
(TIBC), total cholesterol, high density lipoprotein (HDL) cholesterol, low density 
lipoprotein (LDL) cholesterol, and triglycerides. For HD patients, dialysis vintage 
was recorded. A detailed medical history questionnaire (see Appendix) was used 
in the control group. 
Parameters of Periodontal Status 
All patients received a full-mouth periodontal examination, which included clinical 
attachment loss (CAL), probing depth (PD), bleeding on probing (BOP), and 
plaque score (PS)[78] at six sites on all teeth. Based in part on work from 
Arrnitage[79] and Offenbacher[80], severe chronic periodontitis was defined as a 
minimum of 2 sites with pocket probing depth (PPD) r5mm, associated with 
r5mm CAL with 230% of sites exhibiting BOP. A subject was considered 
periodontally healthy if all of the following criteria were met: 1) full-mouth BOP 
~ 3 0 %  of sites, 2) fewer than 2 sites with PPD >4mm and 3) fewer than 2 teeth 
per quadrant with evidence of CAL r5mm. 
3. Statistical analysis 
All continuous variables were tested for normality. When a continuous variable 
was not normally distributed it was treated with logarithmic transforma,tion to 
achieve normality. Data were analyzed using Student's t test, ANOVA, and post- 
hoc Bonferroni testing. A p value of s0.05 was considered statistically significant. 
A computer software program' was used for the statistical analyses. 
D. Results: 
1. Population characteristics 
Population demographics of the test and control groups are presented in Table 2. 
The control group had more female and younger participants compared to the 
test group, although these differences did not reach statistical significance. The 
test group contained significantly more diabetics than the control group (35.0 
percent versus 7.6 percent, p=0.0001). 
2. General periodontal findings 
Periodontal findings between CKD and control subjects are listed in Table 3 and 
Figures 1-3. Severe periodontitis was found in 47.4 percent of CKD subjects, 
compared to 15.4 percent of controls (p=0.02). Control subjects had significantly 
- -  - 
SPSS 16, SPSS Inc. 
fewer missing teeth than CKD subjects (mean 4.62k0.56 versus 8.0923.23, 
p=0.01). Compared to healthy controls, CKD subjects had significantly higher 
mean PD (2.66k0.09mm versus 2.420.1 Omm, p=0.03) and CAL (3.21 k0.18mm 
versus 2.4720.10mrn1 p=0.004) (Figure 2). As shown in Figure 3, CKD subjects 
had significantly more sites with CAL;rSmrn (mean 16.80k4.22 percent versus 
2.5551.5 percent, p=0.001). There were no significant differences in mean PS 
and BOP between CKD and control groups, although both parameters tended to 
be higher in the CKD group. 
3. Periodontal findings and dialysis status 
The periodontal data of the study population stratified into three groups based on 
CKD stage (CKD 3-4lPre-diaysis, CKD 5/HD, Healthy) are shown in Table 4 and 
Figures 4-6. Although severe periodontitis was more prevalent in the 
hemodialysis and pre-dialysis groups compared to controls, the difference did not 
reach statistical significance. 'There were significant differences in PD (p=0.049), 
CAL (p=0.002), CAL15mm (p=0.016), and missing teeth (p=0.030) among the 
groups. Pre-dialysis patients had significantly more missing teeth than healthy 
controls. HD subjects had significantly higher mean PD (2.8020. I I rrlm versus 
2.420.1 Omm, p<0.05), CAL (3.3220. 19mm versus 2.47k0.1 Omm, p<0.05), and 
CAL25mm (22.01k6.49 percent versus 2.55kI .5 percent, p<0.05) compared to 
control subjects. Pre-dialysis subjects also had higher PD and CAL compared to 
controls, but 'this difference only reached significance for CAL (3.06+_0.244mm 
versus 2.47*0.10mm, ~ ~ 0 . 0 5 ) .  There was no statistical difference in mean BOP 
or PS among the three groups (p>0.05). 
E. Discussion 
In our study, severe periodontitis was prevalent in 47.4 percent of CKD patients, 
compared to 15.4 percent of controls. This difference was statistically significant. 
Additionally, when comparing continuous periodontal parameters, mean PD and 
CAL emerged as statistically significant. The difference in the mean values of 
continuous periodontal parameters (CAL, PD) between CKD and healthy groups 
was explained by the significantly higher percentage of diabetics in the CKD 
group as compared to the control group that has been shown to positively affect 
severity of periodontitis[81]. A possible solution to controlling this variable could 
be to exclude diabetics in our study population, although this would limit the 
number of CKD subjects as diabetes is the leading cause of renal failure, 
accounting for 44 percent of new cases in 2005[82]. Chuang and co-workers[83] 
compared 43 diabetic with 85 non-diabetic ESRD patients on HD. Decreased 
salivary flow and pH was associated with increased caries rates in the diabetic 
group but no difference was reported for gingival inflammation or periodontitis. 
While the CKD group had a higher prevalence of periodontitis, BOP was similar 
among the groups. This is likely due to the similar plaque scores between CKD 
and control patients, as presence of plaque has been associated with gingival 
inflammation, and mechanical removal of plaque is followed by clinical changes 
associated with healthy gingiva[84]. In spite of similar plaque scores, CKD 
patients had more periodontal destruction than healthy controls. This can be 
explained by the significantly higher percentage of diabetics in the CKD group, as 
diabetes is an established risk factor for gingivitis and periodontitis[48, 851. It is 
unknown whether the dental plaque of CKD patients differs in composition from 
that of healthy controls, but studies corr~parirlg plaque pH of children with chronic 
renal failure compared to renal transplant or healthy children have shown the 
plaque from children with ESRD to be significantly more alkaline. It has been 
postulated that this difference in plaque pH may account for the low prevalence 
of caries in the CKD population[86], but it is unknown if this affects periodontal 
status. Also, CKD patients on HD are characterized by uremia, which has been 
associated with defects in lymphocyte and monocyte function[87]. Lymphocytes 
and monocytes play important roles in immune response, and defects in the 
function of these cells have been associated with aggressive forms of periodontal 
disease[88] and therefore may play a role in the increased amount of periodontal 
destruction seen in these patients. 
The data on the prevalence of periodontitis in CKD populations are conflicting. 
Direct comparison of results to other studies is difficult owing to the different 
definitions of periodontitis used by different research groups. The periodontitis 
definition in this project was selected based on the current classification system 
used by the American Academy of Periodontology[79] that defines severe 
periodontitis as the presence of a single site with CAL 25mm. BOP was added to 
this definition because a recent classification system [80] that identified new 
clinical and distinct biologic phenotypes at the biofilm-gingival interface (BGI) 
based upon DNA checkerboard analyses of plaque bacteria, serum 
immunoglobulin G (IgG) titers to bacteria, and gingival crevicular fluid (GCF) 
levels of inflammatory mediators includes BOP as one defining parameter. For 
example, a BGI-deep lesionlmoderate bleeding was defined as one or more sites 
with PD 24mm and BOP extent scores between 10 and 50 percent. 
The prevalence of severe periodontitis did not differ significantly among control, 
hemodialyis, and pre-dialysis groups. Compared to HD patients, there were no 
significant differences with pre-dialysis subjects in regard to any of the 
periodontal parameters measured. Pre-dialysis patients had significantly higher 
mean CAL compared to controls. These results are different than those from 
Borawski[75], who found significantly higher mean CAL among hemodialysis 
patients compared to pre-dialysis patients. A direct corr~parison of prevalence of 
periodontitis to our results could not be performed owing to differences in the 
definition of periodontal disease, but pre-dialysis patients in Borawski's study had 
significantly higher community periodontal index and treatment needs (CPITN) 
scores than those patients on hemodialysis or controls, indicating an increased 
prevalence and severity of periodontal disease in this population. The 
differences in sample size conipared with our pilot study could also account for 
the conflicting results. Further large-scale studies with a standardized approach 
to evaluating the periodontal status of pre-dialysis populations are needed. 
The cross-sectional design of this study prevents us from determining any cause- 
effect relationships between periodontal disease and chronic kidney disease. It 
is possible that this association may be due to a direct cellular effect on the 
nephron unit or its vasculature by periodontal pathogens. While a direct cellular 
invasion of periodontal pathogens in renal tissue has yet to be shown, 
periodontal pathogens have been shown to invade coronary and aortic 
endothelial cells[89, 901. Furthermore, periodontitis patients have been shown to 
have chronic and recurrent episodes of low-level bacteremia[91, 921. Some have 
hypothesized that bacteria may be filtered out of the blood at the glomerulus, 
where these organisms or their products may invade capillary endothelium or 
mesangial cells/matrix[93]. Future studies are needed to confirm the role of 
periodontal pathogens on renal tissue. 
II1.Serum Inflammatory Markers in CKD Patients 
Objectives: 
1. Hypothesis: 
Inflammatory periodontal disease in CKD patients contributes to 
systemic inflammatory response, which may affect clinical 
outcomes. 
2. Specific Objectives: 
Using a population of stable CKD patients and healthy controls, we 
aimed to: 
a> Assess the levels of the systemic inflammatory markers, 
IL-6 and CRP, in the presence or absence of periodontal infection 
in HD and pre-dialysis CKD populations compared to healthy 
controls. 
Introduction: 
The role of inflammation in the pathogenesis of periodontal disease and other 
systemic diseases has been documented[94-961. Although the exact pathogenic 
mechanism remains unclear, one hypothesis is that elevated amounts of 
inflammatory cytokines are released locally from the diseased periodonti~~m into 
the bloodstream, leading to an increase in serum cytokines at the systemic level, 
thus contributing to disease outcomes. Diseased periodontal tissues have been 
shown to possess higher levels of IL-6 than healthy tissues[97, 981, and serum 
CRP has been shown to be elevated in patients suffering from periodontitis[99]. 
Additionally, evidence has shown that treatment of periodontal disease may be 
associated with reduced serum levels of inflammatory markers and 
corresponding irr~provement in glycemic contro1[100] and endothelial function[63], 
although the evidence is conflicting. 
The leading cause of mortality in CKD patients is cardiovascular disease, 
regardless of CKD stage [ I  01, 1021 [ I  031. Elevated levels of inflammatory 
markers such as CRP and IL-6 are known predictors of cardiovascular outcomes 
in the HD population[l04], and are linked to hypoalbuminemia, malnutrition, 
ery'thropoietin resistance and increased mortality[l05, 1061. 
It has been recognized that approximately 30-50% of CKD[107] [I081 patients 
have evidence of a systemic inflammatory response which may be caused by 
persistent infections[27]. Since periodontitis as a chronic persisting infection has 
been associated with systerr~ic elevation of inflammatory markers [99], it may 
also predict poor outcomes in CKD populations. Therefore, we hypothesize that 
severe periodontitis may represent a "non-traditional" risk factor for elevated 
systemic inflammation in CKD populations. 
Materials & Methods: 
1. Subject recruitment 
Based on studies by Borawski et a1.[75] and Rao et a1.[104], our power analysis 
estimated it would be necessary to recruit 43 HD, 43 pre-dialysis, and 15 healthy 
controls for CRP assessment and 29 HD, pre-dialysis, and healthy controls for 
IL-6 assessment. For the purposes of this analysis in this pilot feasibility study, 
the same group of subjects described in Objective 1 was used. The subjects 
signed a consent form that was approved by the Institutional Review Board (IRB) 
as described before. Medical and biochemical data were retrieved from the 
medical records as described in Objective 1. 
2. Blood sampling and analysis 
In HD subjects, blood samples were drawn from the arterial end of the vascular 
access immediately before initiation of the HD and then stored at -70' until 
assay. In pre-dialysis and control subjects, 15 ml venous blood was collected 
prior to the oral clinical examination by a certified phlebotomist. 
Within 2 hours of blood collection, sera were separated after clotting for 30 
minutes at 4OC, followed by centrifugation at 3,000 x g for 15 minutes. Aliquots 
were stored at -80°C until testing. Sera were coded and analyzed in duplicate by 
€LISA' without the knowledge of the periodontal disease or CKD status of the 
study participants. The IL-6 and CRP assay analytical sensitivities were 2.0 pglml 
and <0.3 mgIL, respectively, and the variation in protein values within runs was 
< I  % for both assays. 
3. Statistical analysis 
Continuous variables were tested for normality and logarithmically transformed if 
skewed. IL-6 and CRP levels were compared among the groups by Student's t 
test, ANOVA, and post-hoc Bonferroni test. Pearson's correlation coefficients 
were calculated to test the associations between serum CRP, serum IL-6, and 
periodontal variables. Any variables that had an association with rr0.5 were 
included at the multivariate regression analysis as confounders. A multivariate 
linear regression model was run, using serum CRP and IL-6 as dependent 
variables and testing periodontitis as a predictor variable and adjusting for 
confounders based on the significance of the correlation coefficient. A p value of 
50.05 was considered statistically significant. 
1 Diagnostic Products, Los Angeles, CA. 

I. Serum inflammatory markers and CKD status 
Serum CRP and IL-6 levels for control and CKD patients are listed in Table 5 and 
shown in Figures 7 and 8. CKD patients had a higher mean CRP levels (median 
3.87, range 0.30-78.35pglml) compared to controls (median 1.41, range 0.42- 
18.00pglml). This difference was statistically significant (p=0.014). Similarly, IL- 
6 levels were higher in CKD patients (median 8.72, range 0.60-9.92pglml) when 
compared to control subjects (median 4.00, range 2.00-5.82pglml). This 
difference was also statistically significant (p=0.038). 
Table 6 and Figures 9 and 10 show CRP and IL-6 levels in subjects according to 
renal status (hemodialysis, pre-dialysis, and controls). There were significant 
differences between the groups for both CRP and IL-6. In regard to serum CRP 
levels, control subjects (median 1.41, range 0.42-1 8.00pglml) had lower values 
than hemodialysis (median 5.78, range 1.87-41.80pglml) and pre-dialysis 
(median 2.48, range 0.30-78.35pglml) patients. This difference reached 
statistical significance for HD palients only ( ~ ~ 0 . 0 5 ) .  There were no significant 
differences between hemodialysis and pre-dialysis groups (p>0.05). Serum IL-6 
levels were significantly elevated in hemodialysis patients (median 10.98, range 
6.01 -29.35pglml) compared to pre-dialysis patients (median 4.00, range 0.60- 
9.92pg/mll p~0.05)  and control subjects (median 4.00, range 2.00-5.92pgIm1, 
pc0.05). There were no significant differences between pre-dialysis and control 
subjects (p>0.05). 
2. Serum inflammatory markers and periodontal status 
Table 7 and Figures 11 -12 show CRP and IL-6 levels in subjects stratified based 
on the periodontal status. Subjects with severe periodontitis had lower serum 
CRP levels (median 2.935, range 0.21-41.8~glml) than periodontally-healthy 
subjects (median 3.26, range 0.42-78.32pg/ml), but this difference was not 
significant (p>0.05). In contrast, IL-6 levels in subjects with severe periodontitis 
(median 6.1 75, range 2.00-29.35pglml) were significantly higher compared to 
subjects without periodontitis (median 4.63, range 2.00-1 1.35, p=<0.05). 
3. Association between inflammatory markers and periodontal 
parameters 
Correlations between serum IL-61CRP levels and periodontal parameters are 
presented in Table 8. Both serum IL-6 and CRP levels were significantly related 
to PS (r=0.385; p=0.039 and r=0.372; p=0.047, respectively). There was a trend 
toward significance for the associations between serum IL-6 levels and CAL 
(r=0.281, p=0.140). In contrast to IL-6, serum CRP levels were highly related to 
CAL (r=0.500, p=0.006) as well as CAL25mm (r=0.409, p=0.027). There was 
also a trend toward significance for the relationships between serum CRP levels 
and BOP (r=0.294, p=0.122) and PD (r=0.307, p=0.106). Furthermore, there 
was a significant correlation between periodontal status and serum IL-6 (r=0.441, 
p=0.045) as well as CRP and IL-6 (r=0.450, p=0.041) among CKD patients. 
Multivariable linear regression analysis models were constructed to assess the 
interaction between medical and periodontal parameters and serum IL-6 and 
CRP levels in the CKD patients. Usirrg serum IL-6 as a dependent variable 
(Table 9), HD status was a significant predictor for elevated serum IL-6 levels 
(p=0.029), but periodontal status was not (p=0.350). The interaction between HD 
and periodontal status was also not significant (p=O. 161). When serum CRP was 
used as the dependent variable (Table lo),  there was a significant effect of 
gender (p=0.028) and BMI (p=0.013), and dialysis status was a significant 
predictor of elevated serum CRP (p=0.012), but periodontal status was not 
(p=0.432). The interaction between HD and periodontal status did not have a 
significant effect on serum CRP levels (p=0.256). 
E. Discussion 
In our study, both serum CRP levels and IL-6 levels were higher in CKD subjects 
compared to controls. CKD is characterized by a chronic state of 
inflammation[33], so these results were expected and are consistent with those 
reported by others[22-241. The sources of inflammation in CKD patients are still 
under investigation, but clotted access grafis[29], atherosclerotic processes[I 091, 
and persistent infections[27, 281 have all been suggested to be contributory 
factors. Residual renal function may also have an important role in the 
inflammatory process. For example, serum IL-6, IL-8, and TNF-alpha levels 
have been shown to be elevated in HD patients compared to healthy 
controls[25]. In addition, patients on peritoneal dialysis have been reported to 
have increased CRP levels during the first year of dialysis[llO]. Animal studies 
also suggest a reduced clearance of pro-inflammatory cytokines when renal 
function is impaired[l 1 1 , 1121. 
Serum CRP levels were significantly higher in HD patients compared to controls. 
While pre-dialysis patients had higher CRP levels compared to controls, this 
difference did not reach statistical significance. Other studies have found CRP 
levels to be elevated in pre-dialysis patients[ll3], and several researchers[ll3- 
11 51 have found an inverse relationship between GFR and CRP levels in pre- 
dialysis patients. The exact reason why there was no significant difference in 
CRP levels between HD and pre-dialysis patients cannot be explained. 
However, the incidence of elevated serum CRP levels has been shown to be 
different among different geographical populations~l16], indicating that causes 
other than dialysis-related factors such as nutrition and lifestyle can also play a 
role in serum CRP levels. Our limited sample size could also explain these 
trends as well as our inability to discern a statistically significant difference 
between the two CKD populations. 
Serum IL-6 levels were significantly higher in HD patients compared to both pre- 
dialysis patients and healthy controls. Our ,findings of increased IL-6 levels in HD 
patients is in agreement with others who have found plasma IL-6 to be elevated 
in these patients[ll7, 1181. The lack of a statistically significant difference in IL-6 
levels between pre-dialysis patients and controls in some of our analysis is in 
contrast to what has been reported by others[l19]. 
IL-6 levels have been shown to predict mortality in both HD and pre-dialysis 
patientsC42, 104, 1 181 and may be a better predictor of mortality than CRPCI 191. 
This leads one to question whether a medical or pharmacological intervention 
can alter this cytokine imbalance to irr~prove outcomes. Statins and ACE- 
inhibitor drugs administered to CKD patients can lower IL-6 levels in both non- 
renal and CKD patients[120-1231, but it is unknown if this affects mortality 
outcomes. 
As expected, serum IL-6 levels were higher in patients with severe periodontitis 
compared to subjects without periodontitis. This is consistent with the findings 
reported by others[97, 981. While there were statistically significant differences in 
IL-6 levels between periodontitis and non-periodontitis groups, this was not the 
case for CRP levels. The finding that CRP levels were higher in non-periodontitis 
patients compared to periodontitis patients is unexpected. Other authors[99] 
have shown CRP to be elevated in patients suffering from periodontitis, and 
treatment of periodontitis has been shown to decrease CRP levels in 
systerr~ically healthy patients[68], so our findings are inconsistent with previous 
reports. This could be accounted for by our limited sample size (n=33) coupled 
with the limited number of patients displaying severe periodontitis (n=12). The 
mechanism for the differences in serum inflammatory mediators in the presence 
of diseased and healthy periodontal tissue is still under investigation. One 
possibility is that these mediators are produced from the periodontium itself. It 
has been shown that gingival fibroblasts from chronic periodontitis lesions 
produce greater amounts of IL-6 than healthy controls[97]. 1L-6 has also been 
found to be elevated in the gingival crevicular fluid[124] and serurn[68] of chronic 
periodontitis patients. This may be due to polymorphisms resulting in an 
increased expression of the IL-6 (-174) gene in the presence of periodontal 
infections[l25]. It has been hypothesized that this increase in pro-inflammatory 
mediators could theoretically spill over into the circulation, thus inducing systemic 
effects11 261. 
Both serum IL-6 and CRP levels were significantly correlated with plaque scores. 
It has been postulated that high-responder individuals produce high levels of 
inflammatory mediators and cytokines as part of their host inflammatory 
response to the presence of plaque[127, 1281 and, consequently, these 
individuals are more susceptible to periodontitis. Based on this evidence, 
however, we would not expect a direct relationship between inflammatory 
mediator level and plaque score. Other authors[74] have found no difference in 
gingival index scores between chronic renal failure patients on HD and 
systemically healthy control patients with similar levels of plaque, suggesting that 
HD patients may exhibit a similar inflammatory response to dental plaque as 
healthy patients. 
The significance of HD status as an independent predictor of serum IL-6 and 
CRP levels in the multivariate analysis was expected, as hemodialysis patients 
have been shown to have elevated serum inflammatory markers compared to 
non-hemodialysis patientst21-241. In our study, periodontal status was not a 
predictor of serum IL-6 or CRP. However, multiple studies performed on non- 
CKD populations have shown that serum IL-6 and CRP levels are elevated in 
periodontal patients when compared to periodontally-healthy controls[65-671, and 
that periodontal treatment can reduce levels of these markers[65]. Further 
studies on CKD populations are needed to verify our findings. The interaction 
between the CKD and periodontal status was not significant for either 
inflammatory marker. The limited sample size of our CKD (n=21) and 
periodontitis (n=12) subjects in this pilot study could account for these findings. 
A limitation of our study was the sample size and the cross-sectional design of 
our study does not allow us to make any conclusions regarding a cause and 
effect relationship between periodontal disease and systemic inflammation. 
Further large-scale, intervention studies are needed. 
IV. Concluding Remarks 
I. Severe periodontitis was found to be significantly more prevalent in a 
stable CKD population compared to healthy controls. There was no 
statistically significant difference in prevalence of severe periodontitis 
between hemodialysis, pre-dialysis, and control subjects. 
2. Serum IL-6 and CRP levels were statistically significantly higher in CKD 
patients compared to healthy controls. For serum IL-6, hemodialysis 
patients had significantly higher levels compared to pre-dialysis and 
control patients. Serum CRP levels were significantly higher in 
hemodialyis and pre-dialysis patients compared to controls. There were 
no significant differences in CRP or IL-6 levels between pre-dialysis and 
control subjects. 
3. Subjects with severe periodontitis had higher serum levels of IL-6 
compared to periodontally-healthy subjects. There were no significant 
differences with regards to serum CRP levels. 
4. HD status was a significant independent predictor of both serum IL-6 and 
CRP levels in CKD patients. 
V. Index (Tables and Figures) 
Table 1: Stages of chronic kidney disease 
Stage 
At increased risk 
Description 
Risk factors for kidney 
disease (e.g. , diabetes, 
high blood pressure, 
family history, older age, 
ethnic group) 
Kidney damage (protein 
in the urine) and normal 
GFR 
Glomen~lar Filtration 
Rate (GFR) 
More than 90 
More .than 90 
3 I Moderate decrease in 
2 
GFR 
Severe decrease in GFR s
Kidney damage and mild 
decrease in GFR 
or kidney transplant 
needed) 
60 to 89 
Table 2: Population characteristics of CKD and control groups 
Table 3: Periodontal characteristics of CKD and control groups 
Severe 47.6 
periodontitis 
CAL (mm) 
BOP (%) 
Missing teeth 
(n) 
3.2120.18 
16.0623.4 
Sites 
CAL25mrn 
(%) 
8.0923.23 
2.4720.10 
1 5.4723.82 
16.8024.22 
0.004 
0.45 
4.6220.56 0.01 
2.55k1.5 0.001 
Figure 1: Percent of subjects with severe periodontitis 
Advanced Periadontitis 
Control CKZI 
Figure 2: Comparison of periodontal parameters (PPD, CAL) between CKD and control 
groups 
Periodontal Parameters 
Figure 3: Comparison of periodontal parameters (BOP, PS, CAL25) between CKD and 
control groups 
Periodontal Parameters 
Table 4: Periodontal characteristics of subjects according to renal status 
a - p50.05 between HD and control subjects 
b - ps0.05 between pre-dialysis and control subjects 
c - p10.05 between HD and pre-dialysis subjects 
Variable 
Severe 
periodontitis 
(%) 
PD (mm) 
CAL (mm) 
BOP (%) 
PS (%) 
Missing teeth 
(n) 
Sites 
CALz5mm 
(%) 
Hernodialysis 
Subjects 
(nm.12) 
45.4 
2.8020.1 la 
3.3220.1 ga 
21.74e4.86 
59.4229.88 
6.4221.03 
22.0126.4ga 
Premdialysii 
Subjects 
(nm9) 
44.4 
2.5720.12 
3.0620.24~ 
9.91k3.59 
40.0721 2.30 
10.6222.65~ 
13.5725.81 
Control 
Subjects 
(n=f3) 
15.4 
2.4+.0.10 
2.47-cO.10 
1 5.4723.82 
43.7927.07 
4.62k0.56 
2.55k1.5 
P-Value 
0.13 
0.049 
0.002 
0.174 
0.300 
0.030 
0.016 I 
Figure 4: Percent of subjects with severe periodontitis according to renal status 
Advanced Periodontitis 
W 
Figure 5: Comparison of periodontal parameters (PPD, CAL) according to renal status 
Periodontal Parameters 
* p 5 0.05 compared to control group 
Figure 6: Comparison of periodontal parameters (BOP, PS, CALr5) according to renal 
status 
Periodontal Parameters 
* p s 0.05 compared to control group 
Table 5: Serum inflammatory markers in CKD and control subjects 
CRP (pglml) 
IL-6 (pg/ml) 
3.87 
8.72 
0.30-78.35 
0.60-9.92 
1.41 
4.00 
0.42-18.00 
2.00-5.92 
0.014 
0.038 
1 
Figure 7 :  Comparison of serum CRP levels between CKD and control subjects 
Serum CRP Levels 
Control 
* p s 0.05 
Serum IL-6 Levels 
* 
Ccrritrsl CKU 
Figure 8: Comparison of serum IL-6 levels between CKD and control subjects 
Table 6: Serum inflammatory markers in subjects according to renal status 
a - p10.05 between HD and control subjects 
b - ps0.05 between pre-dialysis and control subjects 
c - p50.05 between HD and pre-dialysis subjects 
Figure 9: Comparison of serum CRP levels according to renal status 
Serum CRP Levels 
* p 5 0.05 compared to control group 
Figure 10: Comparison of serum IL-6 levels according to renal status 
Serum. l L-6 Levels 
14 3 
* I  
I T 
p 5 0.05 compared to control group 
** p 10.05 compared to pre-dialysis group 
Table 7: Serum inflammatory markers in subjects according to periodontal status 
Serum CRP Levels 
3 3 
Variable 
CRP (pglml) 
IL-6 (pglml) 
Figure 11 : Comparison of serum CRP levels according to periodontal status 
Non-Periodontitis 
Subjects 
(nm22) 
I 
3.26 
4.63 
P-Value 
0.286 
0.01 5 
Range 
0.42-78.32 ' 
2.00-1 1.35 
Periodontitis 
Subjects 
(n31 2) 
' Median 
2.935 
6.1 75 
Range 
0.21-41.8 
2.00-29.35 
Figure 12: Comparison of serum IL-6 levels according to periodontal status 
Serum IL-6 Levels 
Table 8: Correlations between inflammatory markers and patient characteristics and 
periodontal variables 
Variable 
Gender 
-I-- 
P 
PS 
PD 
CAL 
CALrBmm 
' Sarum IL-6 Sarum CRP 
I 
Table 9: Multivariable linear regression analysis in CKD patients with serum IL-6 as the 
dependent variable 
Age (years) 0.938 
(yeslno) 
Glucose (mgldl) 0.662 
status*Periodontal 
status 
Periodontitis 
status (yeslno) 
0.350 
Table 10: Multivariable linear regression analysis in CKD patients with serum CRP as 
the dependent variable 
Age (years) 0.165 
Dialysis status 0.012 
(yeslno) 1 
BMI 0.01 3 
Dialysis 0.256 
status*Periodontal 
1 Periodontitis 
status (yeslno) 
0.432 
VI. Appendix 
1) Medical History Questionnaire for Control Subjects 
Universiv of Connecticut Health Center 
School of Dental Medim~c, UnlversiQ Derltists 
MEDICAL HISTORY QZTlf8TIOI8RADLE 
( W e n t  or Guardian to answer for child under 18 years of agc ) 
Name M - F -Date 0rBh-t.b .- .--______ 
Address -_.__II_-._-__X ..__ _ __-  
7- 
Telephone: IHome) . - . (Work) Hekht. - Weight  -- 
Today's Date Occupation 
- --*- .-------.-- -.---.-.- I APaacr ~ U ; Q Y D ~ + - ~ ~ J  af&@g-BithOl YE$ or NO. NU in bLnk wpacee arban indicated. ANSWERS 
I bBE P Q R " O ~ ~ Q R D S  OMY AND AS& COWmEWT&U. -7 
1. My last medical physic4 cxminarion was on (approx.) 
. -.--- 
2. ?'he name & addrcs8 OK my personal physician is 
- . .- ---- 
3 Are you now under the care of a physician ................................................................ YES N O  
If yes, what is the condition being treated ............ . 
4. Have you had any serious iUness or aperation ................................................................... YES NO 
l i  yes, what was the ilincss or operntion 
. .- .. -- 
5. Have you b e n  hospitalized within the past 5 years ....................................................... YES KO 
If yes, what was the problem 
-. .. - 
... 
. . <-LIE;E.r-Y-.. _" :..:>--_- 
6. 110 you have or have you had m y  of the lollowing diseases or problems. 
Rheumatic Kever or rheumatic heart disease ......................................................... YES NO 
abnormalities present since birth.. ............................................................. YfES NO 
Cardiovascular disease (heart wuble,  heart attach, angma, stroke, high 
blood p~rruure, heart murmur.) ................ .. .................................................... YES NO 
................................... Do jvu have discomfort or pressure in the chest upon cxertion YES NO 
.................... ................................ Art  you mw rhort of b w t h  after mild exercise  Yi3S NO 
................................................................................................ Do your ankles oweU YES NO 
Do you get short of hrrath whan you lie down, or do you requim* 
.......................................... ................ extra pillows you &cp .............. .. .... YES NO 
.......................................................... Have you been DM you have a h e w  murmur Y&S NO 
Asthma or hay fever .............. . .............................................................. YES N U  
Hives ur a skin rash ................................................................................................ YES NO 
........... Fainting spells or scizures .................. ... ....................................... . YES NO 
Diabetes ................................................................................................................... YES NO 
..................................................................................... Jaundice or liver disca se... YES NO 
Hepatitis ................................................. ... ........................................................ YES NO 
............................................................................ Arthritis or other Joint problems YES NO 
...................... ................................................................. Stomach ulcers ... ... YES NO 
Kidney e o q b k  ...................................................................................................... YES NO 
............................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Dialysis patient .... YES NO 
........... ......................................................................................... Tuberculosis , YES NO 
Do you have a persistent cough or cough up blwd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  YES N O  
Venereal diseuse ..................................................................................................... YES NO 
AIDS/ ARC or FIN+.. ........................ ...................... ... . . . . . . . . . . . . . . . . . . . . . .  /YES NO 
Other (list) --.-.- ---. ..... .-- . .-. -. . . . . . . . . .  -- 
7. Have you had surgery or radiarion treatment for n tumor, cancer or other condition 
........................ of your head or neck . ......... ........................................................ YES N O  
8 Have you hnd abnormal bleeding assocrated with prenuue extnlslrvrJs, surgery or traurr~a. YES NO 
9.  Do you h ~ v e  any blood disorder such a s  anemia, including siclde cell anerriia . . . . . . . . . . . .  YES NO 
10. Are you a hemophiliac .................,...........,.................................................................... YES NO 
11. Are you a present or pact IV drug user .................................................................... YES NO 
12. Are you a t  increased risk for the HP virus ~r AIDS ....................................................... YES NO 
1 13. Are you taking any drug or medicine ......................................................................... YES NO 
14. Are you taking any of the following: 
Antibiotics or sulfa drugs ............................... YES NO j Drugs for heart troublc lr 
\ dipjralis ................................ YES N O  
Anucoagukarlts: (blood thinners) ....................... YES KO / Nirroylycrrin . . . . . . . . . . . . . . . . . . . . . . .  YES NO 
Medicine for high blood pressure ...................... YES NO ; A~~tihisturnmc ........................ YES NO 
Steroids (Prednisone, Cortisone) ....................... YES NO ' 01.al corltrsrceprive or other hor-rllorlal 
Drugs that change your mood. ................... YES NO 1 therapy ................................. YES NO 
Aspirin ............................. ......... .................. YES NO Anuconvulsarlt dmgs ................ YES No 
Insulin, tolbutamide (Orinase) or . Sedatives or slecp~ng pilla .......... YES NC 
similar drug. ...............  ................................ YES NO / Othel. d ~ ~ g s  --..,- 
IS. L)o you suffer from any birth defect or other disability ................................................... YES NO 
16 Are you allergic or have you reacted adversely to: 
Local anesthetics ........................................... YES NO i IodL~e or X.-my dyes . . . . . . . . . . . . .  Yb;S NO 
Penicillin or other antibiotics .......................... YES NO . Cod~inc o r  other :rarcoucs . . .  YES NO 
Sulfa drugs .............. . ........................... YES NO i Other 
Aspirin.. ......................................................... YES KO 
17 Have you had nriy serious trouble assoc~ated with any prevlouv drrltaf treament . . .  YOS NO 
If yes, e x p h n  -- 
........................... 18. Do you have any disease, condition, or. problem not Listed above YES NO 
If so, please explain 
......... 19. Does your ernpluyment expose you regularly t o  x-rtiys or other' ionl ing  radiation YES NO 
20. Are you wearing contact lenses .................................................................................... YES NO 
7-,- - -- - -. -.. .... ... ~ . ^ . : : j . : . ~ i i * . i ~ . w - - . .  ------,.- -_.I"X i.+L43 
21. Arc you pregnant or have you recently missed a menstrrw.l period.. .............................. YES NO 
22. Are you presently breast feeding ................................................................................ YES NO 
Chief dental complaint (why did you come to the dentist today?) __- 
TO THE BEST OF MY KNOWLEDGE, THE ABOVE MFORlldATlON 18 COkWLETE ARD ACCURATE 
Signature ol klient or Legal Guardian 
* 
2) Medical Data Extraction Form for CKD Subjects 
Hernodialysis and Predialysis Patient 
Chart Review 
.. ... .. 
SECTION 1: PARTICIPANT DEMOGRAPHICS 
. .. . ..... --.- .... ,. . . . . . . . . . . . . . . . . . . . .  7 
I .  Pt ID: 
-- ( 3  digit tC)  
I 2. 008: . I  -
3. Ethnicity: 
1- Asian [ ] 2-Black [ ] 3-White [ 1 4-Native Hawaiian!Pacific Islander [ ] 
5-Am IndiAlaska Native [ ] 6-H~spanic [ J 7-Unknown [ ] 
4 Gender: male 1 ] female [ ] 
- - . . -  .. 
 SECT^^ 
-- .- . -... .. 
5. Does the patient have history of diabetes? Y [ ] N [ 1 
If yes. Type I [ ] Type l i  [ I  Insultn-requiricg [ ] 
6. Is the patlent a smoker? Current [ I  Former [ ] Never srncked 1, ] 
lOlnfect~on wRhm the last 2 months (vascular access/f~stula UTI, bronch~!!~,  
peritonitis. prieurnorla, abdom~rlal abscess elc) 
- - .- 
CB td 
1 tees ;,i:12:;r ra<,e 3 ::,stc:%j ~f cadi3vjsci .  a: 3 i 5 ~ 3 ~ E : )  .< : !  N j 
- -5  1':'2<s 3Ppf;p:!Jid ,:I;~,;I:CS.S 
12. Does the patient have history of hypertension'? 
y [ l  N I 1  
: 3. What is the patient's yre-dialysis k~dney disease diagnosis? (Please specify 
etiology of underlying disease) 
- .... - -.-..................... . . . . . . . . . . .  
-- 
SECTION 3: Biochemical data (Most recent) 
............................................................ ... ...-. ...... 
14 Serum alburn~n 
15 Blood urea nltrogen (BUN) -. . 
16. Creatinine:.. - 
17. Ferritin level. ,_ ".--a- 
18.Total Iron B~nding Capacity (TIBC) 
19.Total cholesterol: 
20. HDL-cholesterol: -. 
22.  Trigycerides: 
23. Dialysis adequacy (KW): (only for he~rlodialysls ~lbjects) 
24. Dialysis vintage (years on d~alys~s) (only for heniod~alys~s subjects) 
............. 
: MEDI 
.- 
25 Has the pattent been on non-stero~dal anu-~nflammatory rnedlcatlon ~ ~ t h i n  the 
last month? 
" I 1  N [ 1  
Dose Duratloq -- --- 
26 Has tlle patterit eve! tael-I en a~ltt-tiypetlipiddin~i '~lads? Y [ ] N [ 1 
Dose: Duration' . 
/ 
27 Please attach medication list: 
., .. ....................... ............................... 
28. Please attach SF-36 questionnaire 
3) Abbreviations used 
ANOVA - Analysis of variance 
AV - Arteriovenous 
BGI - Biofilm-gingival interface 
BMI - Body mass index 
BOP - Bleeding on probing 
BUN - Blood urea nitrogen 
CAL - Clinical attachment loss 
CKD - Chronic kidney disease 
CRP - C reactive protein 
CVD - Cardiovascular disease 
ELlSA - Enzyme-linked irr~munosorbent assay 
ESRD - End stage renal disease 
GFR - Glornerular filtration rate 
HD - Hemodialysis 
HDL - High density lipoprotein 
Ig - lmmunoglobulin 
IL - Interleukin 
IRB - Institutional Review Board 
LDL - Low density lipoprotein 
PPD - Pocket probing depth 
TlBC - Total iron binding capacity 
UCHC - University of Connecticut Health Center 
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